{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:22:57Z","timestamp":1791559377867,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,6]]},"DOI":"10.7759\/cureus.112160","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:36:06Z","timestamp":1783362966000},"source":"Crossref","is-referenced-by-count":1,"title":["Losartan-Associated Sub-fulminant Hepatitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Kanwarpreet","family":"Sadhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakshand","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Mehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunera","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithvika","family":"Badugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogundele","family":"Tosin Arinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ballu","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/ijnrd.s7038","article-title":"Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?","volume":"3","author":"Ripley E","year":"2010","unstructured":"Ripley E, Hirsch A. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?. Int J Nephrol Renovasc Dis. 2010, 3:93-8. 10.2147\/ijnrd.s7038","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(01)02321-9","article-title":"The role of the renin-angiotensin system in the development of cardiovascular disease","volume":"89","author":"Unger T","year":"2002","unstructured":"Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002, 89:3A-9A. 10.1016\/s0002-9149(01)02321-9","journal-title":"Am J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/2249-4863.141635","article-title":"Losartan-induced ischemic hepatocellular hepatotoxicity: a case report and literature review","volume":"3","author":"Al-Halawani MZ","year":"2014","unstructured":"Al-Halawani MZ, Thawabi M, Asslo F, Shaaban H, Shamoon F, Baddoura WJ. Losartan-induced ischemic hepatocellular hepatotoxicity: a case report and literature review. J Family Med Prim Care. 2014, 3:272-4. 10.4103\/2249-4863.141635","journal-title":"J Family Med Prim Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.04.001","article-title":"Risk factors for idiosyncratic drug-induced liver injury","volume":"138","author":"Chalasani N","year":"2010","unstructured":"Chalasani N, Bj\u00f6rnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010, 138:2246-59. 10.1053\/j.gastro.2010.04.001","journal-title":"Gastroenterology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson E","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-9. 10.1002\/hep.20800","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana RJ","year":"2010","unstructured":"Fontana RJ, Seeff LB, Andrade RJ, Bj\u00f6rnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010, 52:730-42. 10.1002\/hep.23696","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49846","article-title":"Marked hepatotoxicity associated with losartan treatment: a case report","volume":"15","author":"Zahedi I","year":"2023","unstructured":"Zahedi I, Sami M, Ijishakin O, Onyemarim H, Cutliff RT, Ezeamii VC. Marked hepatotoxicity associated with losartan treatment: a case report. Cureus. 2023, 15:e49846. 10.7759\/cureus.49846","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200205000-00022","article-title":"Losartan-induced hepatic injury","volume":"34","author":"Tabak F","year":"2002","unstructured":"Tabak F, Mert A, Ozaras R, et al.. Losartan-induced hepatic injury. J Clin Gastroenterol. 2002, 34:585-6. 10.1097\/00004836-200205000-00022","journal-title":"J Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki A","year":"2011","unstructured":"Suzuki A, Brunt EM, Kleiner DE, et al.. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011, 54:931-9. 10.1002\/hep.24481","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4769","article-title":"Losartan-induced severe hepatic injury: a case report and literature review","volume":"11","author":"Patti R","year":"2019","unstructured":"Patti R, Sinha A, Sharma S, Yoon TS, Kupfer Y. Losartan-induced severe hepatic injury: a case report and literature review. Cureus. 2019, 11:e4769. 10.7759\/cureus.4769","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/405983-losartan-associated-sub-fulminant-hepatitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:36:06Z","timestamp":1783362966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/405983-losartan-associated-sub-fulminant-hepatitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.112160","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,6]]}}}